The Role of Renal Dysfunction in Chronic Heart Failure of Rheumatic Etiology and Therapeutic Possibilities

Chronic heart failure (CHF) is one of the most common clinical syndromes among the global population and is considered a severe complication of cardiovascular diseases, as well as one of the leading causes of mortality and disability [23]. CHF has been diagnosed in 1.0–2.6% of the population in Europe, 2.2% in the United States, and 7% in the Russian Federation, with this prevalence increasing with age [12, 15]. Rheumatic heart defects play a significant role in the etiology of CHF, which is associated with their high prevalence, including in Uzbekistan [13, 25]. In CHF, renal dysfunction develops in the form of cardiorenal syndrome, which intensifies the interconnection between the heart and kidneys [25]. In recent years, growing attention has been paid to the cardio- and nephroprotective effects of empagliflozin, a drug from the group of selective sodium-glucose cotransporter 2 (SGLT2) inhibitors [19]. The measures adopted in Uzbekistan to improve healthcare quality and prevent non-communicable diseases further underscore the relevance of this study [PD-60, 2022]. This article examines renal dysfunction and the effects of empagliflozin in CHF that has developed on the background of rheumatic heart defects.